Breakthrough Clinical Results

IDEAYA Biosciences will host an R&D Day on September 8, 2025, to present clinical data updates across its pipeline and outline its future growth strategy. The event will feature presentations from IDEAYA's senior leadership and key opinion leaders. The company, focused on precision medicine oncology, is celebrating its 10th anniversary and will highlight its pipeline of targeted therapies, including those focused on synthetic lethality and antibody-drug conjugates. The event will be held in-person in New York City and virtually.

Emerging Mechanism of Action

Emerging Mechanisms of Action in Cancer Treatment

Immunotherapy Approaches

• Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway remain central to cancer immunotherapy
• PD-L1 has an intrinsic role in cancer cells beyond T cell inhibition, affecting cell proliferation and tumor growth
• Siglec-15 functions via different but complementary mechanisms to PD-L1, with expression being mutually exclusive with PD-L1
• TREM2 on tumor-associated macrophages and myeloid-derived suppressor cells is a promising target that enhances outcomes of anti-PD-1 immunotherapy
• PD-1-TREM2 scFv-secreting CAR-T cells showed highly effective tumor elimination
• TIM-3 is an immuno-myeloid regulator with sabatolimab as a novel immunotherapy targeting it through a dual mechanism of immune reactivation and direct targeting of leukemic cells

Combination Therapies

• Chemo-immunotherapy combinations show benefit in subgroups of triple-negative breast cancer patients
• Sub-efficacious doses of targeted therapies combined with anti-PD1 demonstrated enhanced anti-tumor activity
• Combination treatments increase Ki67+/CD8 T-cells and Granzyme B+/CD8 in tumors
• The combination of CUDC-101 (HDAC inhibitor) and docetaxel significantly reduced tumor growth in prostate cancer by suppressing the AKT and ERK1/2 signaling pathways

Tumor Microenvironment Modulation

• CircFAM13B represses immune evasion and enhances immunotherapy sensitivity by inhibiting glycolysis and acidic tumor microenvironment
• Tumor-infiltrating lymphocytes and tumor-associated macrophages are important in the tumor microenvironment
• Emerging approaches aim to modulate the tumor microenvironment to enhance immune system involvement
• BTK inhibitors affect various immune cells and influence cytokine profiles in the tumor microenvironment

Novel Targets and Pathways

• Caldesmon is proposed as a novel target for cancer therapy
• BRD9 is overexpressed in prostate cancer patients, especially those with metastatic disease

• JAK inhibitors demonstrated efficacy in hemophagocytic lymphohistiocytosis with different mechanisms:

• JAK1 inhibitor targeting inflammatory and metabolic pathway genes

• JAK2 inhibitor targeting cell proliferation and metabolism genes

• JAK1/2 inhibitor exerting the greatest transcriptional changes

• Bruton's tyrosine kinase (BTK) inhibitors have revolutionized treatment of chronic lymphocytic leukemia and other B cell malignancies

Epigenetic Modulation

• Histone deacetylases (HDAC) overexpression significantly suppresses tumor suppressor genes in pancreatic cancer

• HDAC inhibitors have shown evidence in:

• Tumor eradication

• Improving T cells activation

• Restoring tumor immunogenicity

• Modulating programmed death 1 interaction

• Targeting HDAC is presented as a strategy to reverse immune evasion in pancreatic cancer

Natural Compounds

• Maslinic acid, a pentacyclic triterpene in common foodstuffs, exhibits inhibitory effects against various cancer cell lines by impacting every cancer hallmark through targeting multiple pathways

Company drugs in pipeline

IDEAYA Biosciences, Inc. Pipeline Indications

Based on the available information, I cannot provide specific details about the drug pipeline indications for IDEAYA Biosciences, Inc. The company is known to operate in the biopharmaceutical sector with a focus on precision medicine approaches, but specific information about their current drug candidates, therapeutic targets, and clinical programs is not available in the provided materials.

IDEAYA Biosciences likely focuses on developing targeted therapies for various indications, potentially including oncology applications and other areas where precision medicine approaches can be beneficial. However, without specific pipeline information, I cannot detail which particular diseases or medical conditions their drug development efforts are addressing.

For the most current and accurate information about IDEAYA Biosciences' pipeline, interested parties should consult the company's official website, recent investor presentations, SEC filings, or clinical trial registries where they would publish updates on their drug candidates and development programs.

The biopharmaceutical industry, particularly companies focused on precision medicine like IDEAYA, typically targets specific genetic mutations or molecular pathways involved in disease progression. These companies often develop small molecule inhibitors, biologics, or other therapeutic modalities designed to address the underlying causes of diseases rather than just treating symptoms.

As the field of precision medicine continues to evolve, companies like IDEAYA Biosciences play an important role in advancing targeted therapies that may offer improved efficacy and safety profiles compared to traditional treatments by focusing on specific patient populations most likely to benefit from their approach.

Company Mechanism of Action